Merck KGaA Signs Cancer-MS Barter Deal With Japan's Ono
This article was originally published in PharmAsia News
Executive Summary
Why pay cash if you can barter asset rights instead? In a duo of agreements announced Oct. 4, Germany's Merck KGaA licensed worldwide rights ex-Japan, Korea and Taiwan to Ono Pharmaceutical Co. Ltd.'s Phase II MS candidate, ONO-4641, while granting Ono Japanese rights to its own Phase III cancer immunotherapy Stimuvax
You may also be interested in...
Merck KGaA Plays On Multiple Initiatives; Aims For 30% Growth In Emerging Markets
MUMBAI - Contrary to what most global CEOs would say about challenges confronting the global pharmaceutical industry, Karl-Ludwig Kley, chairman of the $12.28 billion German chemicals and pharmaceuticals conglomerate Merck KGaA, says he doesn't believe the pharma business model is broken, despite dwindling R&D pipelines, increasing spend and diving sales as fewer blockbusters make it to market
Merck KGaA Plays On Multiple Initiatives; Aims For 30% Growth In Emerging Markets
MUMBAI - Contrary to what most global CEOs would say about challenges confronting the global pharmaceutical industry, Karl-Ludwig Kley, chairman of the $12.28 billion German chemicals and pharmaceuticals conglomerate Merck KGaA, says he doesn't believe the pharma business model is broken, despite dwindling R&D pipelines, increasing spend and diving sales as fewer blockbusters make it to market
Deals Of The Week: Bristol/Ono, Bristol/Ambrx, Merck Serono/Peptimmune
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.